Geron Corporation (GERN)’s Stock Is Buy After Today’s Huge Increase

March 14, 2018 - By Marguerite Chambers

Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.24, from 1.21 in 2017Q2. It fall, as 10 investors sold Geron Corporation shares while 27 reduced holdings. 11 funds opened positions while 25 raised stakes. 61.75 million shares or 0.63% more from 61.36 million shares in 2017Q2 were reported.
Wisconsin-based Northwestern Mutual Wealth Management Company has invested 0% in Geron Corporation (NASDAQ:GERN). D E Shaw & Inc holds 0% or 14,856 shares in its portfolio. Proshare Advsrs Lc owns 99,896 shares. Parametric Portfolio Assocs Ltd Liability Com reported 19,871 shares stake. Moreover, Mufg Americas Holdings has 0% invested in Geron Corporation (NASDAQ:GERN). Savings Bank Of America De reported 0% stake. Fernwood Investment Mngmt Limited Liability Corporation owns 16,000 shares for 0.02% of their portfolio. State Board Of Administration Of Florida Retirement Sys, a Florida-based fund reported 138,882 shares. Lpl Financial Ltd Co reported 18,100 shares stake. Two Sigma Secs Ltd Liability has 0% invested in Geron Corporation (NASDAQ:GERN) for 14,954 shares. 553,937 were accumulated by Citadel Advsr Ltd Liability Corp. North Star Inv Mngmt Corporation holds 0% of its portfolio in Geron Corporation (NASDAQ:GERN) for 2,000 shares. Assetmark invested in 335 shares or 0% of the stock. First Eagle Investment Management Limited Company accumulated 144,700 shares or 0% of the stock. Jane Street Group Limited Liability Corp invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN).

The stock of Geron Corporation (NASDAQ:GERN) is a huge mover today! The stock increased 5.37% or $0.16 during the last trading session, reaching $3.14. About 2.87 million shares traded or 16.61% up from the average. Geron Corporation (NASDAQ:GERN) has risen 13.81% since March 14, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.
The move comes after 8 months positive chart setup for the $499.99M company. It was reported on Mar, 14 by We have $3.27 PT which if reached, will make NASDAQ:GERN worth $20.00 million more.

Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on March, 16 after the close. They expect $-0.04 earnings per share, up 20.00 % or $0.01 from last year’s $-0.05 per share. After $-0.04 actual earnings per share reported by Geron Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Geron Corporation (NASDAQ:GERN) Ratings Coverage

Among 3 analysts covering Geron (NASDAQ:GERN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Geron had 5 analyst reports since August 8, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Saturday, August 8 by Zacks. The rating was maintained by MLV with “Buy” on Monday, August 10. The rating was maintained by Stifel Nicolaus on Tuesday, August 1 with “Hold”. Piper Jaffray maintained Geron Corporation (NASDAQ:GERN) on Monday, December 7 with “Overweight” rating. FBR Capital maintained it with “Outperform” rating and $5 target in Tuesday, September 13 report.

More recent Geron Corporation (NASDAQ:GERN) news were published by: which released: “Imetelstat Might Be Brought Down By Hy’s Law” on February 20, 2018. Also published the news titled: “Geron: The Good, The Bad And The Ugly” on February 14, 2018.‘s news article titled: “Why Geron Corporation Stock Is Rising Today” with publication date: March 13, 2018 was also an interesting one.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $499.99 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: